INC Research, inVentiv Health combination has net revenue exceeding $3 billion, psychiatry-focused site network

Mega Merger

INC Research, inVentiv Health combination has net revenue exceeding $3 billion, psychiatry-focused site network

Raleigh-based contract research organization INC Research (Nasdaq: INCR) – which recently announced plans to merge with Boston-based inVentiv Health– has launched a new site network focused on psychiatry.

According to Tracey Gashi, executive director, Site & Patient Access, at INC Research, “INC Research’s investigative site strategy aligns with our long-term view of how clinical development will evolve, where reliable technology and increased access to data means investigative sites will increasingly work with multiple providers to identify and involve patients in clinical research. We believe focusing on site collaboration is more prudent in the current market than acquiring site networks and site management organizations,” acquiring site networks and site management organizations. Our collaboration model allows us to develop strong, highly structured and measurable partnerships with all providers of patient data and enables us to focus on matching the best site with the right patients to the protocol.”

Last year INC Research introduced the Psychiatry Catalyst Site Network as part of a program that includes networks in oncology and vaccines clinical research. It was designed to bolster collaborations with clinical research sites worldwide. The psychiatry network will include 32 sites selected by the company. INC Research has conducted more than 115 psychiatry studies over the last five years.

Because the market is highly competitive, CROs are attempting to diversify their offerings. According to Gashi, “Expansion of the Catalyst site networks is based on business need and an assessment of current business and potential pipeline in specific therapeutic areas or indications. INC Research has a strong history of CNS clinical research and as a result has continued to see a strong pipeline across CNS as a whole but also specifically in Schizophrenia and [major depressive disorder].”

As Alexandria Wise-Rankovic, senior vice president, Clinical Development at INC Research, explained, “I would call psychiatry a steady area of work that we have seen pharma invest in for many years. We have always had a healthy network of investigators but by formalizing it, we position ourselves and our investigators to commit to performance. This is an important logical step in our continued commitment to sites and to our customers.”

In other news, INC Research Holdings, Inc. announced the completion of a merger with inVentiv Health, Inc., a leading, privately held global CRO and Contract Commercial Organization (“CCO”). The merger creates the only fully integrated biopharmaceutical solutions organization, including an end-to-end CRO and CCO, according to the companies. The combined company will be called INC Research/inVentiv Health until a relaunch under a new brand in 2018. 

According to Alistair Macdonald, Chief Executive Officer, INC Research/inVentiv Health, “INC Research/inVentiv Health will address new market realities through shared clinical and commercial expertise, data and insights to meet the needs of biopharmaceutical companies of all sizes. This strategic combination enhances our ability to facilitate approvals and product launches in multiple markets worldwide, and the value we offer to employees, customers and our shareholders.”

As Michael Bell, Executive Chairman of the Board of Directors and President, Commercial Division, INC Research/inVentiv Health, concluded, “Customers will benefit from enhanced global scale, deep therapeutic alignment and integrated solutions, including market access and Real World Evidence. We look forward to supporting our talented management team and are committed to enabling our customers to speed the delivery of therapies to the patients who need them most.”